EICHOR
● Recruiting
Busulfan Sample Collection Study
Condition: Subjects Treated With Busulfan · Sponsor: Saladax Biomedical, Inc.
About this study
Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.
This description comes directly from the study's public registry record.
Talk to the study team
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
Locations (3)
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago, Illinois, United States | Active Not Recruiting |
| Rutgers Cancer Institute | New Brunswick, New Jersey, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Active Not Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.